贝伐珠单抗联合替莫唑胺治疗复发性脑胶质瘤的效果及对血清TGF-β、GFAP、VTN、YKL-40水平的影响  

Effect of bevacizumab combined with temozolomide in the treatment of recurrent brain gliomas and its influences on serum TGF-β,GFAP,VTN and YKL-40 levels

作　　者：袁兴 王乃冰 YUAN Xing;WANG Naibing(Neurosurgery Department,Xi'an International Medical Center Hospital,Xi'an 710100,China)

机构地区：[1]西安国际医学中心医院神经外科,陕西西安710100

出　　处：《临床医学研究与实践》2025年第11期66-69,共4页Clinical Research and Practice

摘　　要：目的探讨贝伐珠单抗联合替莫唑胺治疗复发性脑胶质瘤的效果及对血清细胞因子的影响。方法选取2020年6月至2022年6月我院接收的100例复发性脑胶质瘤患者为研究对象,根据治疗方案不同将其分为对照组和观察组,各50例。对照组给予常规放疗+替莫唑胺治疗,观察组在对照组基础上联合贝伐珠单抗治疗。比较两组的治疗效果。结果治疗后6个月,两组的复发率、生存率无显著差异(P>0.05);治疗后12个月,观察组的复发率低于对照组(P<0.05);治疗后12个月,两组的生存率无显著差异(P>0.05)。观察组的总有效率(ORR)高于对照组(P<0.05);两组的疾病控制率(DCR)无显著差异(P>0.05)。治疗后,观察组的转化生长因子-β(TGF-β)、胶质纤维酸性蛋白(GFAP)、玻连蛋白(VTN)、甲壳质酶蛋白-40(YKL-40)水平均低于对照组(P<0.05)。治疗后,观察组的功能领域、总体健康状况领域及症状领域评分优于对照组(P<0.05)。结论贝伐珠单抗联合替莫唑胺治疗复发性脑胶质瘤能有效控制病灶进展,改善血清因子水平,降低患者复发率,提高生存质量。Objective To investigate the effect of bevacizumab combined with temozolomide in the treatment of recurrent brain gliomas and its influences on serum cytokines.Methods A total of 100 patients with recurrent brain gliomas admitted to our hospital from June 2020 to June 2022 were selected as the research objects.According to different treatment schemes,the patients were divided into control group and observation group,with 50 cases in each group.The control group was treated with conventional radiotherapy and temozolomide,and the observation group was treated with bevacizumab on the basis of the control group.The therapeutic effects of the two groups were compared.Results At 6 months after treatment,there were no significant differences in recurrence rate and survival rate between the two groups(P>0.05);at 12 months after treatment,the recurrence rate of the observation group was lower than that of the control group(P<0.05);at 12 months after treatment,there was no significant difference in survival rate between the two groups(P>0.05).The overall response rate(ORR)of the observation group was higher than that of the control group(P<0.05);there was no significant difference in disease control rate(DCR)between the two groups(P>0.05).After treatment,the levels of transforming growth factor-β(TGF-β),glial fibrillary acidic protein(GFAP),vitronectin(VTN)and chitinase protein 40(YKL-40)in the observation group were lower than those in the control group(P<0.05).After treatment,the scores of functional areas,overall health status areas and symptom areas in the observation group were better than those in the control group(P<0.05).Conclusion Bevacizumab combined with temozolomide in the treatment of recurrent brain gliomas can effectively control the progression of the lesion,improve the levels of serum factors,reduce the recurrence rate of patients,and improve the quality of life.

关 键 词：贝伐珠单抗 替莫唑胺 复发性脑胶质瘤 

分 类 号：R739.41[医药卫生—肿瘤]